Ein Verfahren zur Arzneimittelüberwachung nach ihrer Zulassung
It has been generally recognized that safety and efficiency tests for drugs are not completed with their admission onto the market. Many undesirable side effects have only been recognized during practical application, such as, for example, in the case of Contergan. Therefore, preventive measures must be taken so that, in case any suspicions arise data for closer checking is available.
KeywordsUndesirable Side Effect Close Check Nicht Nach Monitoring Nurse Intensive Drug Monitoring
Unable to display preview. Download preview PDF.